MedTrace Logo

Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

NCT00927537 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2052

Last updated 2013-09-04

No results posted yet for this study

Summary

The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months

Conditions

Interventions

DRUG

Telmisartan (Kinzal/Pritor, BAY68-9291)

Patients under daily life treatment receiving Kinzal according to local drug information.

DRUG

Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide

Patients under daily life treatment receiving Kinzalplus according to local drug information.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • Switzerland

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00927537 on ClinicalTrials.gov